{
    "clinical_study": {
        "@rank": "16597", 
        "acronym": "MPI", 
        "arm_group": [
            {
                "arm_group_label": "Metformin only", 
                "arm_group_type": "Experimental", 
                "description": "metformin 750mg(D-1), metformin 500mg (D1)"
            }, 
            {
                "arm_group_label": "Metformin and Pantoprazole", 
                "arm_group_type": "Experimental", 
                "description": "pantoprazole 40mg(D-2)/ metformin 750mg + pantoprazole 40mg(D-1)/metformin 500mg + pantoprazole 40mg(D1)"
            }, 
            {
                "arm_group_label": "Metformin and Rabeprazole", 
                "arm_group_type": "Experimental", 
                "description": "rabeprazole 20mg(D-2)/metformin 750mg+rabeprazole 20mg(D-1)/metformin 500mg+rabeprazole 20mg(D1)"
            }
        ], 
        "brief_summary": {
            "textblock": "This study aims to investigate the effect of proton pump inhibitor on the pharmacokinetics\n      and pharmacodynamics of metformin in healthy Korean men."
        }, 
        "brief_title": "Clinical Trial to Investigate the Effect of Proton Pump Inhibitor on the Pharmacokinetics and Pharmacodynamics of Metformin", 
        "completion_date": {
            "#text": "December 2012", 
            "@type": "Actual"
        }, 
        "condition": "Healthy", 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  healthy male subject aged 20 to 45 at screening\n\n          -  A body weight in the range of 50 kg (inclusive) - 100 kg (inclusive) with ideal body\n             weight range of +- 25%\n\n          -  subjects who decide to participate voluntarily and write a informed consent form\n\n        Exclusion Criteria:\n\n          -  subjects who have clinically significant disease of cardiovascular, respiratory,\n             renal, endocrinological, hematological, gastrointestinal, neurological(central\n             nervous system), psychiatric disorders or malignant tumor\n\n          -  Subject judged not eligible for study participation by investigator."
            }, 
            "gender": "Male", 
            "healthy_volunteers": "Accepts Healthy Volunteers", 
            "maximum_age": "45 Years", 
            "minimum_age": "20 Years"
        }, 
        "enrollment": {
            "#text": "24", 
            "@type": "Actual"
        }, 
        "firstreceived_date": "May 10, 2013", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01857609", 
            "org_study_id": "MPI"
        }, 
        "intervention": [
            {
                "arm_group_label": "Metformin only", 
                "intervention_name": "Metformin", 
                "intervention_type": "Drug", 
                "other_name": "Diabex"
            }, 
            {
                "arm_group_label": "Metformin and Pantoprazole", 
                "intervention_name": "Metformin and Pantoprazole", 
                "intervention_type": "Drug", 
                "other_name": "Diabex, Pantoloc"
            }, 
            {
                "arm_group_label": "Metformin and Rabeprazole", 
                "intervention_name": "Metformin and Rabeprazole", 
                "intervention_type": "Drug", 
                "other_name": "Diabex, Pariet"
            }
        ], 
        "intervention_browse": {
            "mesh_term": [
                "Metformin", 
                "Pantoprazole", 
                "Proton Pump Inhibitors", 
                "Rabeprazole"
            ]
        }, 
        "is_fda_regulated": "No", 
        "keyword": [
            "Metformin", 
            "Proton pump inhibitor", 
            "Drug interaction"
        ], 
        "lastchanged_date": "May 15, 2013", 
        "location": {
            "facility": {
                "address": {
                    "city": "Seoul,", 
                    "country": "Korea, Republic of"
                }, 
                "name": "Seoul National University Bundang Hospital"
            }
        }, 
        "location_countries": {
            "country": "Korea, Republic of"
        }, 
        "number_of_arms": "3", 
        "official_title": "The Cross-Over Study to Investigate the Effect of Proton Pump Inhibitor on the Pharmacokinetics and Pharmacodynamics of Metformin in Healthy Korean Men.", 
        "overall_official": {
            "affiliation": "Department of Clinical Pharmacology and Therapeutics, Seoul National University Bundang Hospital, Seoul, Korea", 
            "last_name": "Jae-Yong Chung, MD, PhD", 
            "role": "Principal Investigator"
        }, 
        "overall_status": "Completed", 
        "oversight_info": {
            "authority": "Korea: Ministry for Health, Welfare and Family Affairs", 
            "has_dmc": "No"
        }, 
        "phase": "Phase 1", 
        "primary_completion_date": {
            "#text": "December 2012", 
            "@type": "Actual"
        }, 
        "primary_outcome": {
            "description": "AUC(area under the plasma concentration-time curve), Cmax(maximum plasma concentration), t1/2", 
            "measure": "AUC(area under the plasma concentration-time curve)", 
            "safety_issue": "No", 
            "time_frame": "Predose and 0.5, 1, 1.5, 2, 2.5, 3, 4, 6, 8, 10, 12h postdose"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01857609"
        }, 
        "responsible_party": {
            "investigator_affiliation": "Seoul National University Bundang Hospital", 
            "investigator_full_name": "Jae Yong Chung", 
            "investigator_title": "Assistant Professor", 
            "responsible_party_type": "Principal Investigator"
        }, 
        "secondary_outcome": {
            "description": "AUG (total area under the serum concentration-time curve for glucose) Gmax(maximum serum glucose concentration)", 
            "measure": "AUG(total area under the serum concentration-time curve for glucose)", 
            "safety_issue": "No", 
            "time_frame": "predose and 15, 30, 45, 60, 90, 120, 150, 180min oral glucose tolerance test"
        }, 
        "source": "Seoul National University Hospital", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Seoul National University Hospital", 
                "agency_class": "Other"
            }
        }, 
        "start_date": "August 2012", 
        "study_design": "Allocation: Randomized, Endpoint Classification: Pharmacokinetics/Dynamics Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "May 2013"
    }
}